guselkumab vs JNJ-78934804

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline

guselkumab · Tremfya

Marketed by Johnson & Johnson

Approved in Ulcerative Colitismonoclonal antibody
Reliable signal

QUASAR/GALAXI · Phase 3 · completed

Only IL-23i to beat ustekinumab head-to-head on endoscopy in a registrational trial — strong differentiator.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: February 2027 · NCT06260163 (registry estimate)

Reported efficacy

Percentage of Participants in Clinical Remission at Week 12: Percentage of Participants in Clinical Remission at Week 12 (Week 12): Placebo 6.5 Percentage of participants (95% CI 2.4 to 10.6) | Combined Guselkumab 400 mg 27.6 Percentage of participants (95% CI 22.4 to 32.8) (met)

Result source: NCT05528510

JNJ-78934804

Developed by Johnson & Johnson

Phase 3 in Ulcerative ColitisCo-antibody combination (guselkumab + golimumab, SC)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2028 · NCT07577856 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointguselkumabJNJ-78934804
Clinical remission (induction)22.6% vs 7.9%+14.7 vs placebo200 mg IV · wk 12 · n 421NCT04033445
2 other results
  • 21.1% vs 22.2% wk 12 · n 71 · Phase 2 · secondary NCT03662542
  • 36.6% vs 22.2% wk 12 · n 71 · Phase 2 · secondary NCT03662542
—Trial running · NCT07577856
Clinical remission (maintenance)50% vs 18.9%+31.1 vs placebo200 mg SC q4w · wk 44 · n 190NCT04033445
1 other result
  • 45.2% vs 18.9% 100 mg SC q8w · wk 44 · n 188 · Phase 3 · primary NCT04033445
—Trial running · NCT07577856
Clinical response (induction)61.4% vs 27.6%+33.8 vs placebo200 mg IV · wk 12 · n 101NCT04033445
3 other results
  • 60.7% vs 27.6% 400 mg IV · wk 12 · n 107 · Phase 3 · primary NCT04033445
  • 74.6% vs 61.1% wk 12 · n 71 · Phase 2 · primary NCT03662542
  • 83.1% vs 61.1% wk 12 · n 71 · Phase 2 · primary NCT03662542
—Trial running · NCT07577856
Endoscopic improvement (induction)—Trial running · NCT04033445—Trial running · NCT07577856
Corticosteroid-free remission (maintenance)—Trial running · NCT04033445—Trial running · NCT07577856

Clinical remission (induction)

guselkumab
22.6% vs 7.9%+14.7 vs placebo200 mg IV · wk 12 · n 421NCT04033445
2 other results
  • 21.1% vs 22.2% wk 12 · n 71 · Phase 2 · secondary NCT03662542
  • 36.6% vs 22.2% wk 12 · n 71 · Phase 2 · secondary NCT03662542
JNJ-78934804
—Trial running · NCT07577856

Clinical remission (maintenance)

guselkumab
50% vs 18.9%+31.1 vs placebo200 mg SC q4w · wk 44 · n 190NCT04033445
1 other result
  • 45.2% vs 18.9% 100 mg SC q8w · wk 44 · n 188 · Phase 3 · primary NCT04033445
JNJ-78934804
—Trial running · NCT07577856

Clinical response (induction)

guselkumab
61.4% vs 27.6%+33.8 vs placebo200 mg IV · wk 12 · n 101NCT04033445
3 other results
  • 60.7% vs 27.6% 400 mg IV · wk 12 · n 107 · Phase 3 · primary NCT04033445
  • 74.6% vs 61.1% wk 12 · n 71 · Phase 2 · primary NCT03662542
  • 83.1% vs 61.1% wk 12 · n 71 · Phase 2 · primary NCT03662542
JNJ-78934804
—Trial running · NCT07577856

Endoscopic improvement (induction)

guselkumab
—Trial running · NCT04033445
JNJ-78934804
—Trial running · NCT07577856

Corticosteroid-free remission (maintenance)

guselkumab
—Trial running · NCT04033445
JNJ-78934804
—Trial running · NCT07577856
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

JNJ-78934804: no structured comparison results are available for Ulcerative Colitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. guselkumab: 4 of 4 rows · JNJ-78934804: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricguselkumab
Dropout rate
2.8%200 mg IVa
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
show 17 more results
—200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
4.1%200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC q4w to 200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—100 mg SC q8w to 200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—100 mg SC q8w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
0.9%400 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
0%Combination Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
1.4%Combination Phase: Guselkumab Mono
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Monotherapy Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Monotherapy Phase: Guselkumab Mono
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Safety Follow-up: Combination Ther
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Safety Follow-up: Guselkumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
Discontinued due to AEs
0.9%200 mg IVa
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
show 17 more results
—200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
1.6%200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC q4w to 200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—100 mg SC q8w to 200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
—100 mg SC q8w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
0%400 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
0%Combination Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
1.4%Combination Phase: Guselkumab Mono
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Monotherapy Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Monotherapy Phase: Guselkumab Mono
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Safety Follow-up: Combination Ther
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Safety Follow-up: Guselkumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
Serious AEs
0.9%200 mg IVa
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
show 17 more results
3%200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
3.8%200 mg SC
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
3%200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
2.3%200 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
2.3%200 mg SC
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
6.5%200 mg SC q4w to 200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
5.6%200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
6%200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
4.3%100 mg SC q8w to 200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
2.5%100 mg SC q8w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
2.7%400 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
1.4%Combination Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
2.8%Combination Phase: Guselkumab Mono
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
4.2%Monotherapy Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
1.4%Monotherapy Phase: Guselkumab Mono
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
0%Safety Follow-up: Combination Ther
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
3.1%Safety Follow-up: Guselkumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
Most frequent reported AEs
200 mg IVa
anaemia 7.4% (placebo 10.2%)
covid-19 5.6% (placebo 4.6%)
abdominal pain 3.7% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
show 17 more results
200 mg IV
anaemia 6% (placebo 10.2%)
upper respiratory tract infection 4.5% (placebo 0%)
colitis ulcerative 3% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg SC
colitis ulcerative 3.8% (placebo 2.8%)
headache 3.8% (placebo 7.4%)
anaemia 2.5% (placebo 10.2%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg IV
anaemia 5% (placebo 10.2%)
covid-19 5% (placebo 4.6%)
headache 3% (placebo 7.4%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg IV
covid-19 7.6% (placebo 4.6%)
colitis ulcerative 4.1% (placebo 2.8%)
nasopharyngitis 2.9% (placebo 1.9%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg SC
covid-19 7% (placebo 4.6%)
colitis ulcerative 5.4% (placebo 2.8%)
anaemia 4.7% (placebo 10.2%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg SC q4w to 200 mg SC q4w
colitis ulcerative 16.1% (placebo 2.8%)
covid-19 6.5% (placebo 4.6%)
abdominal pain 3.2% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg SC q4w
covid-19 18.4% (placebo 4.6%)
colitis ulcerative 16.8% (placebo 2.8%)
pyrexia 6.4% (placebo 4.6%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
200 mg SC q4w
colitis ulcerative 13.1% (placebo 2.8%)
covid-19 10.1% (placebo 4.6%)
arthralgia 8% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
100 mg SC q8w to 200 mg SC q4w
covid-19 13% (placebo 4.6%)
anaemia 8.7% (placebo 10.2%)
colitis ulcerative 8.7% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
100 mg SC q8w
covid-19 14.2% (placebo 4.6%)
colitis ulcerative 10.2% (placebo 2.8%)
arthralgia 6.1% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
400 mg IV
anaemia 8.1% (placebo 10.2%)
headache 5.4% (placebo 7.4%)
arthralgia 3.6% (placebo 2.8%)
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
anaemia 5.6%
colitis ulcerative 5.6%
headache 5.6%
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
anaemia 8.5%
upper respiratory tract infection 7%
neutropenia 5.6%
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
colitis ulcerative 8.5%
upper respiratory tract infection 8.5%
headache 4.2%
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
anaemia 8.6%
headache 7.1%
colitis ulcerative 5.7%
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
anaemia 0%
colitis ulcerative 0%
headache 0%
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
anaemia 1.5%
colitis ulcerative 1.5%
headache 0%
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for 6 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

guselkumab

Clinical Response 61.4% (n=101) vs 27.6% (n=105) placebo @ 12wk200 mg IV
responder rate · % of participants
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
show 3 more results
60.7% (n=107) vs 27.6% (n=105) placebo @ 12wk400 mg IV
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
74.6% (n=71) vs 61.1% (n=72) Golimumab @ 12wk
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
83.1% (n=71) vs 61.1% (n=72) Golimumab @ 12wk
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
Clinical Remission 22.6% (n=421) vs 7.9% (n=280) placebo @ 12wk200 mg IV
responder rate · % of participants
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
show 4 more results
50% (n=190) vs 18.9% (n=190) placebo @ 44wk200 mg SC q4w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
45.2% (n=188) vs 18.9% (n=190) placebo @ 44wk100 mg SC q8w
NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3
21.1% (n=71) vs 22.2% (n=72) Golimumab @ 12wk
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
36.6% (n=71) vs 22.2% (n=72) Golimumab @ 12wk
NCT03662542 · Phase 2 · registry result, not featured evidence · combination

Crohn's Disease

Shared mechanism: IL-23 p19 · full Crohn's Disease pipeline

guselkumab · Tremfya

Marketed by Johnson & Johnson

Approved in Crohn's Diseasemonoclonal antibody
Reliable signal

QUASAR/GALAXI · Phase 3 · completed

Only IL-23i to beat ustekinumab head-to-head on endoscopy in a registrational trial — strong differentiator.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: March 2027 · NCT05347095 (registry estimate)

Reported efficacy

superior to ustekinumab on pooled endoscopic endpoints (met)

Result source: QUASAR/GALAXI

JNJ-78934804

Developed by Johnson & Johnson

Phase 3 in Crohn's DiseaseCo-antibody combination (guselkumab + golimumab, SC)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2028 · NCT07577843 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointguselkumabJNJ-78934804
Clinical remission (induction)—Trial running · NCT03466411—Trial running · NCT07577843
Endoscopic response (induction)—Trial running · NCT03466411—Trial running · NCT07577843
Clinical remission (maintenance)—Trial running · NCT03466411—Trial running · NCT07577843
Endoscopic response (maintenance)—Trial running · NCT03466411—Trial running · NCT07577843

Clinical remission (induction)

guselkumab
—Trial running · NCT03466411
JNJ-78934804
—Trial running · NCT07577843

Endoscopic response (induction)

guselkumab
—Trial running · NCT03466411
JNJ-78934804
—Trial running · NCT07577843

Clinical remission (maintenance)

guselkumab
—Trial running · NCT03466411
JNJ-78934804
—Trial running · NCT07577843

Endoscopic response (maintenance)

guselkumab
—Trial running · NCT03466411
JNJ-78934804
—Trial running · NCT07577843
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

JNJ-78934804: no structured comparison results are available for Crohn's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. guselkumab: 3 of 4 rows · JNJ-78934804: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricguselkumab
Dropout rate
12.3%200 mg IV q4w followed by 100 mg SC q8w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
show 7 more results
2%200 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
5.4%200 mg IV q4w followed by 100 mg SC q8w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
8.6%200 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
11.5%200 mg IV q4w followed by 100 mg SC q8w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
20.5%1200 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
12.3%600 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
5.3%200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Discontinued due to AEs
—200 mg IV q4w followed by 100 mg SC q8w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
show 7 more results
—200 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
—200 mg IV q4w followed by 100 mg SC q8w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
—200 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
—200 mg IV q4w followed by 100 mg SC q8w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
—1200 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
—600 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
—200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Serious AEs
8.2%200 mg IV q4w followed by 100 mg SC q8w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
show 7 more results
4.1%200 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
12.8%200 mg IV q4w followed by 100 mg SC q8w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
9.9%200 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
8.8%200 mg IV q4w followed by 100 mg SC q8w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
6.8%1200 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
6.8%600 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
7.9%200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Most frequent reported AEs
200 mg IV q4w followed by 100 mg SC q8w
arthralgia 11% (placebo 7%)
nasopharyngitis 11% (placebo 9.3%)
crohn's disease 8.2% (placebo 11.6%)
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
show 7 more results
200 mg IV q4w followed by 200 mg SC q4w
covid-19 14.9% (placebo 0%)
headache 10.8% (placebo 9.3%)
arthralgia 9.5% (placebo 7%)
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
200 mg IV q4w followed by 100 mg SC q8w
covid-19 12.2% (placebo 0%)
upper respiratory tract infection 10.1% (placebo 4.7%)
arthralgia 9.5% (placebo 7%)
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
200 mg IV q4w followed by 200 mg SC q4w
covid-19 20.5% (placebo 0%)
upper respiratory tract infection 8.6% (placebo 4.7%)
arthralgia 7.3% (placebo 7%)
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
200 mg IV q4w followed by 100 mg SC q8w
covid-19 18.2% (placebo 0%)
upper respiratory tract infection 9.5% (placebo 4.7%)
crohn's disease 6.8% (placebo 11.6%)
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
1200 mg IV q4w followed by 200 mg SC q4w
nasopharyngitis 11% (placebo 9.3%)
headache 9.6% (placebo 9.3%)
arthralgia 5.5% (placebo 7%)
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
600 mg IV q4w followed by 200 mg SC q4w
headache 13.7% (placebo 9.3%)
nasopharyngitis 12.3% (placebo 9.3%)
anaemia 8.2% (placebo 2.3%)
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
200 mg
pyrexia 39.5%
headache 15.8%
nasopharyngitis 10.5%
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

guselkumab

CDAI -159.8 vs -34.4 placebo score @ 12wk200 mg IV q4w followed by 100 mg SC q8w
absolute change · score
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
show 2 more results
-143.7 vs -34.4 placebo score @ 12wk1200 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
-139.2 vs -34.4 placebo score @ 12wk600 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
Clinical Response W12 Clinical Remission W48 54.8% (n=146) vs 11.8% (n=76) placebo @ 48wk200 mg IV q4w followed by 200 mg SC q4w
responder rate · % of participants
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
show 3 more results
49% (n=143) vs 11.8% (n=76) placebo @ 48wk200 mg IV q4w followed by 100 mg SC q8w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
48% (n=150) vs 12.5% (n=72) placebo @ 48wk200 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
46.9% (n=143) vs 12.5% (n=72) placebo @ 48wk200 mg IV q4w followed by 100 mg SC q8w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
Clinical Response W12 Endoscopic Response W48 38.4% (n=146) vs 5.3% (n=76) placebo @ 48wk200 mg IV q4w followed by 200 mg SC q4w
responder rate · % of participants
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
show 3 more results
39.2% (n=143) vs 5.3% (n=76) placebo @ 48wk200 mg IV q4w followed by 100 mg SC q8w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
36% (n=150) vs 5.6% (n=72) placebo @ 48wk200 mg IV q4w followed by 200 mg SC q4w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
33.6% (n=143) vs 5.6% (n=72) placebo @ 48wk200 mg IV q4w followed by 100 mg SC q8w
NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3
Clinical Response 52.6% (n=38) @ 4wk200 mg
responder rate · % of participants
No placebo or comparator arm
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 20 Participants as posted
show 11 more results
65.8% (n=38) @ 8wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 25 Participants as posted
78.9% (n=38) @ 12wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 30 Participants as posted
73.7% (n=38) @ 16wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 28 Participants as posted
73.7% (n=38) @ 20wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 28 Participants as posted
78.9% (n=38) @ 24wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 30 Participants as posted
76.3% (n=38) @ 28wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 29 Participants as posted
76.3% (n=38) @ 32wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 29 Participants as posted
76.3% (n=38) @ 36wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 29 Participants as posted
73.7% (n=38) @ 40wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 28 Participants as posted
76.3% (n=38) @ 44wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 29 Participants as posted
81.6% (n=38) @ 48wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 31 Participants as posted
Clinical Remission 44.7% (n=38) @ 4wk200 mg
responder rate · % of participants
No placebo or comparator arm
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 17 Participants as posted
show 11 more results
50% (n=38) @ 8wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 19 Participants as posted
60.5% (n=38) @ 12wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 23 Participants as posted
60.5% (n=38) @ 16wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 23 Participants as posted
57.9% (n=38) @ 20wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 22 Participants as posted
65.8% (n=38) @ 24wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 25 Participants as posted
65.8% (n=38) @ 28wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 25 Participants as posted
65.8% (n=38) @ 32wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 25 Participants as posted
68.4% (n=38) @ 36wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 26 Participants as posted
60.5% (n=38) @ 40wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 23 Participants as posted
65.8% (n=38) @ 44wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 25 Participants as posted
76.3% (n=38) @ 48wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 29 Participants as posted
PRO-2 Remission 15.8% (n=38) @ 4wk200 mg
responder rate · % of participants
No placebo or comparator arm
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 6 Participants as posted
show 11 more results
31.6% (n=38) @ 8wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 12 Participants as posted
42.1% (n=38) @ 12wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 16 Participants as posted
42.1% (n=38) @ 16wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 16 Participants as posted
50% (n=38) @ 20wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 19 Participants as posted
47.4% (n=38) @ 24wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 18 Participants as posted
55.3% (n=38) @ 28wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 21 Participants as posted
50% (n=38) @ 32wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 19 Participants as posted
52.6% (n=38) @ 36wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 20 Participants as posted
55.3% (n=38) @ 40wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 21 Participants as posted
60.5% (n=38) @ 44wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 23 Participants as posted
57.9% (n=38) @ 48wk*200 mg
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 22 Participants as posted
SES-CD -6.4 score @ 48wk200 mg
absolute change · score
No placebo or comparator arm
NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: guselkumab's landscape · JNJ-78934804's landscape